Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease Donanemab in Early Symptomatic Alzheimer Disease